National Comprehensive Cancer Network

About NCCN

NCCN Flash Update: NCCN Guidelines® and NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Bladder Cancer. These NCCN Guidelines® are currently available as Version 5.2017.

  • Principles of Systemic Therapy
    • First-line chemotherapy for locally advanced or metastatic disease
      • For cisplatin ineligible, “Pembrolizumab” was added as a standard option with a category 2A designation for:
        • Bladder cancer
        • Upper GU tract tumors: Renal pelvis
        • Upper GU tract tumors: Urothelial carcinoma of the ureter
        • Urothelial carcinoma of the prostate
        • Primary carcinoma of the urethra (urothelial carcinomas only)

*For your reference, the previous update (Version 4.2017) to the NCCN Guidelines for Bladder Cancer, published on May 17, 2017, is available at the following link:

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit

To view the NCCN Guidelines for Patients®, please visit

Free NCCN Guidelines apps for iPhone, iPad, and Android smartphones & tablets are now available! Visit

About NCCN Flash Updates™ 
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)
275 Commerce Drive, Suite 300
Fort Washington, PA 19034
Telephone: +1 215.690.0300 Fax: +1 215.690.0280 
Access information on permissions and licensing of NCCN Content  

© 2017 National Comprehensive Cancer Network. All Rights Reserved.